IgA Nephropathy Models

Well-Established Induction Protocol with CCl4, LPS, and BSA

Provides a detailed experimental schedule for establishing IgAN-like pathology in BALB/c mice over an 8-week induction period. The model recapitulates core clinical features of human IgAN, including splenomegaly, glomerular mesangial proliferation, capillary basement membrane thickening, and glomerular IgA deposition.

Quantitative Efficacy Endpoints

Includes spleen index measurements as a marker of systemic immune activation, with significant increases in the model group and marked reduction following prednisone treatment, confirming therapeutic response.

Renal Histopathology by H&E Staining

Features representative H&E-stained kidney sections demonstrating severe mesangial proliferation and marked capillary basement membrane thickening in the model group, with moderate pathological changes observed in the treatment group, supporting semiquantitative histopathological scoring.

Glomerular IgA Deposition by Immunofluorescence

Presents immunofluorescence analysis of renal IgA deposition, a hallmark feature of IgAN. Prednisone treatment significantly reduced glomerular IgA deposition compared with the untreated model group, validating the model's responsiveness to standard-of-care therapy.

Actionable Study Design Framework

Outlines a clear treatment initiation timeline (Week 9 post-induction) with a 3-week continuous dosing regimen prior to sample collection, facilitating straightforward translation to your own study planning.

Download the full case study to access complete induction protocols, histopathological images, immunofluorescence data, and experimental timelines. Accelerate your IgAN therapeutic development with Ace Therapeutics' validated preclinical model platform.

You might be interested in...